Cancer Biomarkers Market Expected to Reach $46.7 Billion by 2035

The global cancer biomarkers market is estimated to grow from USD 28.6 billion in 2025 to USD 46.7 billion by 2035, at a CAGR of 5%. The market is expected to experience growth due to advancements in genomic, proteomic, metabolomic, and microRNomic profiling, as well as the emergence of powerful proteomic and genomic technologies. Close to 100 novel cancer biomarker solutions are available in the market, with majority of them using next-generation sequencing for the assessment of cancer biomarkers.

The global cancer biomarkers market is projected to expand significantly, growing from USD 28.6 billion in 2025 to USD 46.7 billion by 2035, at a CAGR of 5% [1]. This growth is fueled by advancements in genomic, proteomic, metabolomic, and microRNA profiling, as well as the emergence of powerful proteomic and genomic technologies. The market is characterized by the availability of nearly 100 novel cancer biomarker solutions, with the majority leveraging next-generation sequencing (NGS) for biomarker assessment.

A recent study published in Nature Communications by Caris Life Sciences demonstrates the transformative potential of AI in cancer biomarker evaluation. The study highlights how AI-based image analysis can enhance the accuracy and efficiency of tissue sample evaluation, potentially guiding immunotherapy decisions and improving patient outcomes [2]. Caris' AI model analyzed data from over 35,000 patients, showing that it can more accurately predict cancer biomarkers and patient survival than conventional methods. In breast cancer, the AI model achieved a hazard ratio (HR) for overall survival of 0.511 (p0.001) compared to traditional PD-L1 IHCs, indicating nearly doubled survival for patients treated with pembrolizumab.

Additionally, a study published in PLOS ONE examined the use of liquid biopsies (LB) in detecting actionable mutations in newly diagnosed advanced non-small cell lung cancer (aNSCLC). The study found that LB-based NGS demonstrated high concordance with tissue biopsies (TB) in detecting single-nucleotide variants (SNVs), with hybrid capture-based assays showing superior performance in identifying gene fusions and MET amplifications [3]. This highlights the complementary role of LB in cancer diagnostics, particularly when tissue samples are unavailable.

These advancements underscore the potential of AI and NGS in revolutionizing cancer biomarker assessment and precision oncology. As the market continues to grow, investors and financial professionals should closely monitor the development and adoption of these technologies to identify promising opportunities and potential risks.

References:

[1] [https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-showing-ai-signature-positive-breast-cancer-patients-live-almost-twice-as-long-as-ai-negative-patients-when-treated-with-a-checkpoint-inhibitor-302522639.html](https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-showing-ai-signature-positive-breast-cancer-patients-live-almost-twice-as-long-as-ai-negative-patients-when-treated-with-a-checkpoint-inhibitor-302522639.html)

[2] [https://pmc.ncbi.nlm.nih.gov/articles/PMC12326616/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12326616/)